Gilead’s experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
More Stories
ARKM up 27% as AI tokens surge
Arkham is among the top trending artificial intelligence-related token as the price of its native token ARKM surges more than...
Southwest Airlines tells staff ‘difficult decisions’ ahead in push to boost profits
Southwest will provide more detail about its plans to raise profits at an investor day on Sept. 26.
AAVE price surges to 2-year high
AAVE price reached highs of $173 on Monday, its highest level since April 2022. TVL has also recovered as the...
What Creates That Cozy, Nestled Home Feeling In A Big City
Have you ever stepped into a home and immediately felt cozy, even in the middle of a busy city? You...
GM’s EV sales momentum is finally building as new vehicle lineup fills out
Two back-to-back record months for GM's EV sales have it within striking distance of Ford through August.
How Foot Locker is waging a comeback after its breakup with Nike
Foot Locker, long reliant on Nike for the bulk of it revenue, is winning over other brands as it transforms...